Novo Nordisk’s Oral Semaglutide Sees 15 Percent Weight Loss and Better Diabetes Control

Multiple clinical trial results from two manufacturers posted in the past several days in The Lancet show high levels of success of both weight loss in obese adults and in control of type 2 diabetes through weight loss.
Source: Drug Industry Daily